For this special edition of Oncology Today, I met with Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research in the management of small cell lung cancer (SCLC), including the recent approval of lurbinectedin as second-line treatment for extensive-stage SCLC. CME information and select publications here.